Engrail Therapeutics

Precision Neuroscience. Transformational Therapies.

Engrail Therapeutics is a biotech company in San Diego, United States, founded in 2019. It has raised $221.0M across 3 rounds, most recently a $157.0M Series B in March 2024.

Employees
11–50
Founded
2019
Business Model
B2B
Total Funding
$221.0M
Last Round
$157.0M Series BMar 2024
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 3 investors for this company. to use credits for reveals, or explore the API.

About

Engrail Therapeutics is a clinical-stage pharmaceutical company focused on developing precision-targeted neuroscience therapies for neuropsychiatric and neurodevelopmental diseases. Its pipeline includes ENX-102 (GABA-A PAM for generalized anxiety disorder) and ENX-104 (for major depressive disorder with anhedonia), both in Phase 2 trials. The company raised a $157M Series B in 2024 to advance its programs.

Funding History

Data from Indexed.vcUpdated
Series BSeries BMar 2024
$157.0M

2 more funding events

  • Extension Round2021
  • Series A2020

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

  • Marketing & SEO ×2
  • DevOps ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech
Extension RoundTotal funding$1.2BNov 2021
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Engrail Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/engrail-therapeutics"><img src="https://indexed.vc/api/badge/company/engrail-therapeutics" alt="Engrail Therapeutics on Indexed.vc" width="260" height="76" /></a>